Published in Am J Kidney Dis on November 20, 2008
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) (FAVORIT) | NCT00064753
BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial. J Am Soc Nephrol (2014) 1.42
Homocysteine and vascular disease: review of published results of the homocysteine-lowering trials. J Inherit Metab Dis (2010) 0.98
Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. Am J Transplant (2012) 0.97
Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol (2010) 0.92
Design considerations and feasibility for a clinical trial to examine coronary screening before kidney transplantation (COST). Am J Kidney Dis (2011) 0.83
Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study. Clin Transplant (2012) 0.83
Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial. J Am Soc Nephrol (2015) 0.79
B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients. Transplantation (2016) 0.78
Cognitive dysfunction and depression in adult kidney transplant recipients: baseline findings from the FAVORIT Ancillary Cognitive Trial (FACT). J Ren Nutr (2011) 0.75
Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Am J Kidney Dis (2016) 0.75
Urinary Markers of Fibrosis and Risk of Cardiovascular Events and Death in Kidney Transplant Recipients: The FAVORIT Trial. Am J Transplant (2017) 0.75
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem (2007) 13.80
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2005) 10.42
Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med (2006) 9.53
Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA (2005) 5.46
Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr (1987) 3.58
Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis (1998) 3.09
Creatinine assay by a reaction-kinetic principle. Clin Chim Acta (1972) 2.26
Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol (2006) 1.67
Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. Nephrol Dial Transplant (2007) 1.67
Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol (2004) 1.48
Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. Am Heart J (2006) 1.09
Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol (1999) 1.06
Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med (1997) 0.84
Hyperhomocysteinemia in renal transplant recipients. Am J Transplant (2002) 0.82
Chronic kidney disease and the transplant recipient. Blood Purif (2003) 0.81
Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. Transplantation (2000) 0.79
Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscler Thromb Vasc Biol (1999) 0.78
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Prevalence of chronic kidney disease in the United States. JAMA (2007) 38.98
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med (2006) 32.81
Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med (2006) 20.27
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet (2010) 18.36
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis (2008) 15.04
Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis (2003) 15.00
Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med (2012) 14.99
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem (2007) 13.80
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Metabolite profiles and the risk of developing diabetes. Nat Med (2011) 12.22
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med (2002) 10.52
Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med (2014) 10.48
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem (2005) 8.93
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48
Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol (2004) 8.21
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med (2013) 7.98
Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med (2007) 7.90
Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. Am J Kidney Dis (2007) 7.86
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA (2008) 7.50
Estimating the number of potential organ donors in the United States. N Engl J Med (2003) 7.49
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis (2002) 7.03
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26
Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int (2011) 6.01
Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol (2007) 6.00
Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int (2008) 5.90
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? J Urol (2008) 5.70
Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med (2009) 5.58
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med (2003) 5.47
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med (2005) 5.45
The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med (2002) 5.33
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. Am J Kidney Dis (2007) 5.06
Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate. N Engl J Med (2015) 5.03
APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med (2013) 5.00
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med (2012) 4.59
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA (2003) 4.44
Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr (2007) 4.37
Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med (2004) 4.34
Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis (2002) 4.34
Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis (2009) 4.30
A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A (2002) 4.22
A predictive model for progression of chronic kidney disease to kidney failure. JAMA (2011) 4.22
Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol (2009) 4.16
Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med (2006) 4.09
Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis (2010) 3.87
Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol (2010) 3.85
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med (2009) 3.73
Patient awareness of chronic kidney disease: trends and predictors. Arch Intern Med (2008) 3.72
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med (2008) 3.71
Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med (2009) 3.69
Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. Hypertension (2007) 3.68
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med (2003) 3.54
Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis (2007) 3.53